摘要
目的研究阿可拉定对人子宫内膜癌细胞株HEC-1B雌激素受体的影响及作用机制。方法体外培养HEC-1B细胞,采用四甲基偶氮唑蓝法(MTT)、逆转录聚合酶链反应法(RT-PCR),观察阿可拉定对HEC-1B细胞增殖作用以及雌激素受体ER-α66和新亚型ER-α36基因表达的影响。结果阿可拉定对HEC-1B细胞增殖具有明显的抑制作用,且抑制作用随药物浓度和给药时间的增加逐渐增强,72h阿可拉定的IC50值为5.26μmol/L。在抑制雌激素受体表达方面,阿可拉定组及阿可拉定联合顺铂组与空白组比较均可明显降低ER-α36的表达(P<0.05,P<0.01);阿可拉定联合顺铂组还可明显降低ER-α66的表达(P<0.01)。结论阿可拉定抑制子宫内膜癌细胞增殖的作用机制可能与其抑制细胞雌激素受体新亚型ER-α36基因表达有关。
Objective To observe the effects of SNG-162 on Cell proliferation and expression of estrogen receptor ER-α36 in human endometrial cancer cell line HEC-1B.
Methods HEC-1B cells were cultured in vitro, HEC-1B cell proliferation was measured by using MTT method and the gene expression of estrogen receptor ER-α66 and ER-α36 were analyzed by the reverse transcriptase polymerase chain reaction （RT-PCR）. Results HEC-1B cell proliferation was significantly inhibited by SNG-162. The inhibitory rates were gradually increased with the concentration and time. After 72 hours, the ICs0value of SNG-162 was 5.26 μmol/L. To compare with the control group, SNG-162 alone or SNG-162 combined with cisplatin groups can significantly reduce the ER-α36 gene expression （P 〈 0.05, P 〈 0.01）. SNG-162 combined with.cisplatin also significantly reduced ER-α66 expression （P 〈 0.01）.
Conclusion SNG-162 inhibits the proliferation-0f endometrial cancer cells, which may be related to the inhibition of estrogen receptor ER-α36 gene expression.
出处
《中国医药生物技术》
CSCD
2012年第2期106-109,共4页
Chinese Medicinal Biotechnology
基金
"重大新药创制"科技重大专项(2009ZX09102-148)
